GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Global Antibiotic Resistance Market, By Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Others), By Disease (cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection), Others (BSI (Bloodstream infection), etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

Global Antibiotic Resistance Market- Recent Developments

In May 2023, Melinta Therapeutics, LLC, a pharmaceutical company, and Xediton Pharmaceuticals Inc, a pharmaceutical company, entered in private agreement for the commercialization and licensing of anti-infective products in Canada, including BAXDELA, KIMYRSA, ORBACTIV, and VABOMERE.
In May 2023, Paratek Pharmaceuticals, Inc., a pharmaceutical company, entered into strategic partnership with Zai Lab (Shanghai) Co., Ltd., a biotechnology company, to develop and commercialize omadacycline, an innovative therapy based on tetracycline chemistry, specifically for patients in China.
In November 2023, Melinta Therapeutics LLC, a pharmaceutical company, collaborated with Venatorx Pharmaceuticals, Inc., a pharmaceutical company, in the U.S. This collaboration aims to commercialize cefepime-taniborbactam, a combination antibiotic designed for complicated urinary tract infections and hospital-acquired bacterial pneumonia in adults.